Insider Selling: Theravance Biopharma (NASDAQ:TBPH) Major Shareholder Sells 273,871 Shares

Theravance Biopharma, Inc. (NASDAQ:TBPH) major shareholder Eli Samaha sold 273,871 shares of the stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $17.23, for a total transaction of $4,718,797.33. Following the sale, the insider directly owned 9,237,279 shares in the company, valued at approximately $159,158,317.17. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Eli Samaha also recently made the following trade(s):

• On Wednesday, July 1st, Eli Samaha sold 37,799 shares of Theravance Biopharma stock. The shares were sold at an average price of $17.00, for a total transaction of $642,583.00.
• On Tuesday, June 30th, Eli Samaha sold 25,027 shares of Theravance Biopharma stock. The stock was sold at an average price of $17.13, for a total transaction of $428,712.51.

Theravance Biopharma Trading Down 0.1%

NASDAQ:TBPH traded down $0.02 during trading hours on Wednesday, reaching $16.98. 1,319,960 shares of the company were exchanged, compared to its average volume of 689,283. The firm has a market cap of $875.32 million, a PE ratio of 7.72 and a beta of 0.17. Theravance Biopharma, Inc. has a twelve month low of $10.82 and a twelve month high of $21.03. The stock’s 50-day moving average is $16.56 and its 200-day moving average is $17.29.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%.The company had revenue of $17.70 million for the quarter. As a group, research analysts anticipate that Theravance Biopharma, Inc. will post 1.54 EPS for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on the company. BTIG Research downgraded Theravance Biopharma from a “buy” rating to a “neutral” rating in a research note on Monday. B. Riley Financial boosted their price objective on shares of Theravance Biopharma from $14.00 to $17.00 and gave the company a “neutral” rating in a report on Tuesday, April 7th. Zacks Research lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 8th. JonesTrading lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Monday. Finally, Oppenheimer cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a report on Thursday, March 5th. One analyst has rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $21.40.

Hedge Funds Weigh In On Theravance Biopharma

Institutional investors have recently modified their holdings of the business. Empowered Funds LLC purchased a new stake in shares of Theravance Biopharma in the first quarter valued at about $900,000. Bank of America Corp DE lifted its stake in Theravance Biopharma by 78.2% in the 1st quarter. Bank of America Corp DE now owns 189,155 shares of the biopharmaceutical company’s stock valued at $3,070,000 after buying an additional 82,978 shares in the last quarter. California State Teachers Retirement System lifted its stake in Theravance Biopharma by 1,649.4% in the 1st quarter. California State Teachers Retirement System now owns 40,761 shares of the biopharmaceutical company’s stock valued at $662,000 after buying an additional 38,431 shares in the last quarter. Quantinno Capital Management LP grew its holdings in Theravance Biopharma by 32.9% during the 1st quarter. Quantinno Capital Management LP now owns 18,038 shares of the biopharmaceutical company’s stock valued at $293,000 after buying an additional 4,463 shares during the last quarter. Finally, Rangeley Capital LLC acquired a new stake in Theravance Biopharma during the 1st quarter valued at $1,672,000. 99.10% of the stock is owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.